JLE

Hépato-Gastro & Oncologie Digestive

MENU

Digestive amyloidosis: From diagnosis to treatment Volume 25, issue 5, Mai 2018

Figures


  • Figure 1

  • Figure 2

  • Figure 3

  • Figure 4

Tables

Authors
1 Centre Hospitalier Lyon-Sud, Service de gastroentérologie, 69495 Pierre-Bénite, France
2 Hôpital Édouard Herriot, Service de médecine interne, 69003 Lyon, France
3 INSERM U1111, Centre International de Recherche en Infectiologie, Université de Lyon, Lyon, France
* Tirés à part

Amyloidosis is a rare entity featured by a misfolding of protein pathology, defined by an extracellular amyloid deposition in tissues. Each amyloidosis is distinguished by the type of fibrillar protein involved, and each form has its own clinical features and treatment. The diagnosis is based on histology after Red Congo staining, polarized light shows a green birefringence which is pathognomonic. Gastrointestinal and hepatic involvement is frequent, and may be the first symptoms of the disease. Thus it is important to think about amyloidosis in case of unexplained clinical presentation as motility disorder, chronic diarrhea, unexplained intestinal malabsorption, intestinal pseudo-obstruction, or hepatosplenomegaly to look for extradigestive impairment and to start a treatment as quickly as possible. Nevertheless, the prognosis remains poor, and mainly depends on cardiac and renal failures.

Licence This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License